ArticleInternational journal of clinical and experimental pathology2015
Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 76 citations in OpenAlex.
- [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.Neuro-oncology · 2024Trial
- Trial
- Somatostatin Receptor Expression and Theranostic Applications Across Non-Neuroendocrine Tumors: A Molecular-to-Clinical Review.International journal of molecular sciences · 2026Review
- Humanized antibody-drug conjugates for Somatostatin receptor 2 (SSTR2)-positive tumor treatment.Molecular cancer therapeutics · 2026Article
- Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors.European journal of nuclear medicine and molecular imaging · 2025Article
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- SUV-max ofJournal of neuro-oncology · 2025Article
- Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.European journal of nuclear medicine and molecular imaging · 2025Article
- Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas.Frontiers in immunology · 2025Article
- Orthotopic meningioma rat model exhibits morphological and immunohistochemical congruency and epigenetic concordance with benign primary patient-derived tumors.Scientific reports · 2024Article
- GLI1-Altered Mesenchymal Tumor with ACTB Fusion and Somatostatin Receptor 2A (SSTR2A) Immunopositivity.Cureus · 2024Article
- Article
- Expression of somatostatin receptors in canine and feline meningioma.Veterinary medicine and science · 2024Article
- DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas.AJNR. American journal of neuroradiology · 2024Observational
- Chronic hyperglycemia and intracranial meningiomas.BMC cancer · 2024Article
- Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023Review
- The usefulness of [European journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are benign brain tumors that are usually to recur. Studies have shown in vitro and in vivo that meningiomas, regardless of histology and classification, express somatostatin receptors (SSTRs). We investigated the immunohistochemical expression of five SSTR subtypes (SSTR1-SSTR5) in tumor tissue sections from 60 patients with diagnosis of meningioma who underwent surgical resection and relating it to patient age and sex, tumor histology, location, regrowth/recurrence and follow-up. Mean (SD) patients age was 53.18 (12.6) years and 44 were women (73.3%). According to the WHO histological grading criteria, 47 (78.3%) meningiomas were grade I, 11 (18.3%) were grade II, and 2 (3.3%) were grade III. All five SSTRs were expressed in our sample, at frequencies ranging from 61.6 to 100%, with a predominance of SSTR2. SSTR5 was more frequently expressed in tumors benign than in tumors malignant (P<0.013). Recurrence-free survival rate at 2 years was 75.2%. There were no significant differences in SSTR expression regarding age, sex, tumor location and regrowth/recurrence. SSTR expression was detected at a significant frequency in this series. SSTR5 showed higher expression in tumors benign supporting the use of these SSTRs in diagnostic of meningiomas and their influence in process of tumorigenesis in meningiomas recurrence.
Indexed as
Identifiers
26722517PMC4680462W2416901715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.